Hlavaty et al developed models for predicting outcome of infliximab therapy in a patient with Crohn's disease (CD). The authors are from University Hospital Gasthuisberg in Leuven, Belgium, and University Hospital Bratislava in Slovakia.
Types of Crohn's disease considered:
(1) refractory luminal
(2) fistulizing
Paramters:
(1) age of the patient
(2) location of involvement
(3) apoptotic pharmacogenetic index (API)
(4) concurrent azathioprine therapy
(5) C-reactive protein (CRP) in mg/L
Model for Refractory Luminal CD
API
Azathioprine
Age and Location
Response
Remission
0 or 1
not given
NA
21%
16%
0 or 1
given
NA
79%
63%
2
NA
age > 40 AND ileal disease
52%
39%
2
NA
age > 40 OR ileal disease
77%
55%
2
NA
neither
84%
71%
3
NA
NA
100%
86%
Model for Fistulizing CD
API
Azathioprine
CRP
Response
Remission
0 or 1
not given
NA
47%
20%
0 or 1
given
NA
100%
50%
2
NA
<= 5 mg/L
73%
20%
2
NA
> 5 mg/L
94%
58%
3
NA
NA
100%
0%
To read more or access our algorithms and calculators, please log in or register.
